OBJECTIVETo study the effects of HuDan Granules on lipid metabolism and antioxidant activity of mice with hyperlipidemia.METHODSSeventy-eight mice were divided into six groups randomly: the normal control group, hyperlipemia group, HuDan Granules high, middle, low dose group and the Simvastatin group. Besides the normal control group, all the mice in the other groups were fed with lipid emulsion for 4 weeks. The Chinese medicine groups were treated with HuDan Granules at the dose of 12,6,3 g/kg, the normal control group and hyperlipemia group were treated with normal sodium, the Simvastatin group were treated with Simvastatin. After 4 weeks, the TC, TG, HDL-C, LDL-C, SOD, GSH-Px and LPO in serum were measured.RESULTSHuDan Granules groups could significantly decrease the serum TC, TG, HDL-C in the experimental hyperlipidemia mice, and markedly increase the level of serum HDL-C. Mean level of serum LPO in the experimental groups treated by HuDan Granules at different dosages were much lower than that in hyperlipidemia group (P<0.05), but higher than the Simvastatin group (P<0.05). And the SOD and GSH-Px activities of serum in the group of HuDan Granules were much higher than those in hyperlipidemia group and the Simvastatin group (P<0.05).CONCLUSIONHuDan Granules can regulate lipid metabolism, enhance the antioxidation and reduce the lipid peroxidation in mice with hyperlipidemia.

01 Jun 1998·Current Medical Science

Effects of huangdan capsule on plasma cGMP and ANP in rats with chronic renal failure

Article

Author: J Chen ; J Zheng ; C Zhang ; S Hong ; S Chen

The model of chronic renal failure (CRF) was made in 5/6 nephrectomized rats and Huangdan capsule was used to treat these rats. The levels of cyclic guanosine monophosphate (cGMP) and atrial natriuretic peptide (ANP) in plasma were examined. The results showed that Huangdan capsule could postpone the increase in the levels of cGMP and ANP, suggesting that by regulating the water and sodium metabolism, Huangdan capsule could ameliorate the glomerular filtration rate, and that Huangdan capsule could lower the levels of cGMP and ANP in plasma via body regulation.

01 Feb 1998·Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine

[Clinical study on effect of huancongdan capsule in treating senile vascular dementia].

Article

Author: Cheng, W ; Zhou, W ; Chen, K

OBJECTIVETo observe the effect of Huancongdan (HCD) capsule on senile vascular dementia (SVD).METHODSSeventy two cases of SVD were divided randomly into two groups. The HCD group (37 cases) were treated with HCD and the control group (35 cases) treated with Hydergine.RESULTSAfter 2 months of treatment, the clinical symptoms, hyponeural defect, self-care capability and abnormal ratio of whole blood viscosity to plasma viscosity in HCD group were significantly different as compared with before treatment (P < 0.05).CONCLUSIONThe effect of HCD for treatment of SVD was affirmative.

100 Deals associated with Hudan Capsule

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hepatitis B, Chronic	Phase 2	CN	Beijing Shijia Jiu Sheng Yuan Pharmaceutical Tech. Co. Ltd	01 Jan 2008
Hepatitis B, Chronic	Phase 2	CN	Shandong Kongfu Pharmaceutical Factory	01 Jan 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Hudan Capsule

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation